Rooney S A, Young S L, Mendelson C R
Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut 06510.
FASEB J. 1994 Sep;8(12):957-67. doi: 10.1096/fasebj.8.12.8088461.
Pulmonary surfactant, a complex material that lines the alveolar surface of the lung, is synthesized in the type II pneumocyte. Surfactant consists largely of phospholipids, of which phosphatidylcholine is by far the most abundant component, and is mainly responsible for surface activity. Surfactant also contains four unique proteins, surfactant protein (SP)-A, SP-B, SP-C, and SP-D, which are synthesized in a lung-specific manner. SP-A and SP-D are glycoproteins (M(r) approximately 30,000-40,000) whereas SP-B and SP-C are small (M(r) approximately 5,000-18,000), extremely hydrophobic proteolipids released from large precursors by proteolysis. Synthesis of surfactant lipids and proteins is developmentally regulated in fetal lung and can be accelerated by glucocorticoids and other hormones. Developing fetal lung in vivo and in organ culture has been used extensively to study regulation of surfactant synthesis and gene expression. Glucocorticoids stimulate the rate of fetal lung phosphatidylcholine biosynthesis and the activity of the rate-regulatory enzyme, cholinephosphate cytidylyltransferase (CYT). The hormone, however, does not increase the amount of CYT; there is evidence that the increase in activity is mediated by increased fatty biosynthesis due to enhanced expression of the fatty acid synthase gene. Glucocorticoids also regulate expression of the SP-A, SP-B, and SP-C genes in the late gestation fetal lung. Hormone response elements and other cis-acting regulatory elements have been identified in the 5'-flanking regions of the SP-A, SP-B, and SP-C genes. Surfactant phospholipids are stored in lamellar bodies, secretory granules in the type II cell, and secreted by exocytosis. Lamellar bodies are also rich in SP-B and SP-C but there are conflicting data on the cellular distribution of SP-A. Secretion of SP-A may be constitutive and occur independently of lamellar bodies. Phosphatidylcholine secretion is a regulated process, and in isolated type II cells it can be stimulated by physiological and other agents that act via at least three signal-transduction mechanisms. After secretion, surfactant is transformed into tubular myelin, and the lipid and protein components are separated as the lipid is inserted into a monolayer at the air-liquid interface. The majority of surfactant is removed from the alveolar space by reuptake into the type II cell by mechanisms that may include receptor-mediated endocytosis. Some components of surfactant are directly recycled into new surfactant whereas other components are degraded.
肺表面活性物质是一种覆盖在肺肺泡表面的复杂物质,由Ⅱ型肺细胞合成。表面活性物质主要由磷脂组成,其中磷脂酰胆碱是迄今为止最丰富的成分,主要负责表面活性。表面活性物质还含有四种独特的蛋白质,即表面活性蛋白(SP)-A、SP-B、SP-C和SP-D,它们以肺特异性方式合成。SP-A和SP-D是糖蛋白(相对分子质量约为30000-40000),而SP-B和SP-C则是小的(相对分子质量约为5000-18000)、疏水性极强的蛋白脂质,由大的前体通过蛋白水解释放。表面活性物质脂质和蛋白质的合成在胎儿肺中受到发育调控,并且可被糖皮质激素和其他激素加速。在体内和器官培养中的发育中的胎儿肺已被广泛用于研究表面活性物质合成和基因表达的调控。糖皮质激素刺激胎儿肺磷脂酰胆碱的生物合成速率以及限速酶胆碱磷酸胞苷转移酶(CYT)的活性。然而,该激素并不会增加CYT的量;有证据表明,活性的增加是由脂肪酸合酶基因表达增强导致的脂肪酸生物合成增加介导的。糖皮质激素还在妊娠晚期胎儿肺中调节SP-A、SP-B和SP-C基因的表达。在SP-A、SP-B和SP-C基因的5'侧翼区域已鉴定出激素反应元件和其他顺式作用调节元件。表面活性物质磷脂储存在板层小体中,板层小体是Ⅱ型细胞中的分泌颗粒,并通过胞吐作用分泌。板层小体也富含SP-B和SP-C,但关于SP-A的细胞分布存在相互矛盾的数据。SP-A的分泌可能是组成性的,并且独立于板层小体发生。磷脂酰胆碱的分泌是一个受调控的过程,在分离的Ⅱ型细胞中,它可被通过至少三种信号转导机制起作用的生理和其他因子刺激。分泌后,表面活性物质转化为管状髓磷脂,并且随着脂质插入气液界面的单分子层中,脂质和蛋白质成分被分离。大多数表面活性物质通过可能包括受体介导的内吞作用的机制被重新摄取到Ⅱ型细胞中,从而从肺泡腔中清除。表面活性物质的一些成分被直接再循环到新的表面活性物质中,而其他成分则被降解。